

LIST OF SCIENTIFIC PUBLICATIONS

updated by October, 2014

Øyvind S. Bruland (MD & PhD)
Professor of Clinical Oncology
Faculty of Clinical Medicine,
University of Oslo
&
Consultant Oncologist
Department of Oncology,
The Norwegian Radium Hospital
Oslo University Hospital

www.bruland.info

Reisbig, R.R., and Bruland, Ø.S.: Dianthin 30 and 32 from *Dianthus caryophyllus*: Two inhibitors of plant protein synthesis and their tissue distribution. *Arch. Biochemistry and Biophysics*, 224, 700-706 (1983).

Reisbig, R.R., and Bruland, Ø.S.: The protein synthesis inhibitors from wheat, barley, and rye have identical antigenic determinants. *Biochemical and Biophysical Research Communications*, 114, 190-196 (1983).

Bruland, Ø.S., Fodstad, Ø., and Pihl, A.: The use of multicellular spheroids in establishing human sarcoma cell lines in vitro. *Int. J. Cancer*, 35, 793-798 (1985).

Bruland, Ø.S., Fodstad, Ø., Funderud, S., and Pihl, A.: New monoclonal antibodies specific for human sarcomas. *Int. J. Cancer*, 38, 27-31 (1986).

Fodstad, Ø., Brøgger, Ø., Bruland, Ø.S., Solheim, Ø.P., Nesland, J.M., and Pihl, A.: Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. *Int. J. Cancer*, 38, 33-40 (1986).

Godal, A., Bruland, Ø.S., Haug, E., Aas, M., and Fodstad, Ø.: Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells. *Br. J. Cancer*, 53, 839-841 (1986).

Bruland, Ø.S., Fodstad, Ø., Skretting, A., and Pihl, A.: Selective radiolocalization of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts. *Br. J. Cancer*, 56, 21-25 (1987).

Bruland, Ø.S., Fodstad, Ø., Stenwig, E. and Pihl, A.: Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. *Cancer Res.*, 48, 5302-5309 (1988).

Haines, D.M., and Bruland, Ø.S.: Immunohistochemical detection of (human) sarcoma-associated antigens in spontaneous canine osteosarcomas. *Anticancer Res.*, 9, 903-908 (1989).

Fjeld, J.G., Bruland, Ø.S., Benestad, H.B., Schjerven, L., Stigbrand, T., and Nustad, K.:

Radio-immunotargeting in immunocompetent animals using intraperitoneal diffusion chambers containing human tumor cells. *Br. J. Cancer*, 62, 573-578 (1990).

Flørenes, V.A., Aamdal, S., Myklebost, O., Mælandsmo, G.M., Bruland, Ø.S., and Fodstad, Ø.: Levels of nm23 messenger RNA in metastatic malignant melanomas: Inverse correlation to disease progression. *Cancer Res.*, 52, 6088-6091 (1992).

Vergote, I.B., Larsen, R.H., DeVos, L.N., Nesland, J.M., Bruland, Ø.S., Bjørgum, J., Alstad, J., Trope, C.G., and Nustad, K.: Therapeutic efficacy of the alpha-emitter ²¹¹At bound on microspheres compared with ⁹⁰Y and ³²P colloids in a murine intraperitoneal tumor model. *Gynecol. Oncol.*, 47, 366-372 (1992).

Haines, D.M., Bruland, Ø.S., Matte, G., Wilkinson, A.A., Meric, S.M., and Fowler, J.D.: Immunoscintigraphic detection of primary and metastatic canine osteosarcoma with F(ab')₂ fragments of osteosarcoma-associated monoclonal antibody TP-1. *Anticancer Res.*, 12, 2151-2158 (1992).

Kjønniksen, I., Winderen, M., Bruland, Ø.S., and Fodstad, Ø.: ^{99m}Tc MDP bone scans of human tumor xenografts in nude mice: Resemblance to corresponding lesions in the patient. *Clin. Exp. Metastasis*, 10, 54 (1992).

Andreasen, Å., Øyjord, T., Hovig, E., Holm, R., Flørenes, V.A., Nesland, J., Myklebost, O., Høie, J., Bruland, Ø.S., Børresen, A.L., and Fodstad, Ø.: p53 abnormalities in different subtypes of human sarcomas. *Cancer Res.*, 53, 468-471 (1993).

Kjønniksen, I., Winderen, M., Bruland, Ø.S., and Fodstad, Ø.: Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. *Cancer Res.*, 54, 1715-1719 (1994).

Lopes, J.M., Bjerkehagen, B., Holm, R., Bruland, Ø.S., Sobrinho-Simoes, M., and Nesland, J.M.: Immunohistochemical profile of synovial sarcomas with emphasis on the epithelial-type differentiation. A study of 49 primary tumors, recurrences and metastases. *Path. Res. Pract.*, 190, 168-177 (1994).

Larsen, R.H., Bruland, Ø.S., Hoff, P., Alstad, J., Lindmo, T., and Rofstad, E.K.: Inactivation of human osteosarcoma cells in vitro by ²¹¹At-TP-3 monoclonal antibody: Comparison with ²¹¹At-labeled bovine serum albumin, free ²¹¹At, and external beam X-rays. *Radiation Research*, 139, 178-184 (1994).

Larsen, R.H., Bruland, Ø.S., Hoff, P., Alstad, J., and Rofstad, E.K.: Analysis of the therapeutic gain in the treatment of human osteosarcoma microclonies in vitro with ²¹¹At-labelled monoclonal antibodies. *Br. J. Cancer*, 69, 1000-1005 (1994).

Larsen, R.H., Hoff, P., Alstad, J., and Bruland, Ø.S.: Preparation and quality control of ²¹¹At-labelled and ¹²⁵I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts. *J. Labelled Compds. Radiopharm.* 34, 773-785 (1994).

Hassfjell, S.P., Hoff, P., Bruland, Ø.S., and Alstad, J.: ²¹²Pb/²¹²Bi-EDTMP. Synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical. *J. Labelled Compds. Radiopharm.*, 34, 717-734 (1994).

Page, R.L., Garg, P.K., Garg, S., Archer, G.E., Bruland, Ø.S., and Zalutsky, M.R.: Positron emission tomographic imaging of osteosarcoma in dogs using an ¹⁸F-labeled monoclonal antibody Fab fragment. *J. Nucl. Med.*, 35, 1506-1513 (1994).

Bruland, Ø.S., Aas, M., Fodstad, Ø., Solheim, Ø.P., Høie, J., Skretting, A., Michaelsen, T., and Pihl, A.: Immunoscintigraphy of bone sarcomas. Results in five patients. *Eur. J. Cancer*, 30, 1484-1489 (1994).

Larsen, R.H., Hoff, P., Vergote, I.B., Bruland, Ø.S., Aas, M., De Vos, L., and Nustad, K.: Alpha-particle radiotherapy with ²¹¹At-labelled monodisperse polymer particles, ²¹¹At-labelled IgG proteins and free ²¹¹At in a murine intraperitoneal tumor model. *Gynecol. Oncol.*, 57, 9-15 (1995).

Lopes, J.M., Bjerkehagen, B., Holm, R., Bruland, Ø.S., Sobrinho-Simoes, M., and Nesland, J.M.: The proliferative activity of synovial sarcomas. An immunohistochemical evaluation of Ki-67 labeling indices of 52 primary and recurrent tumors. *Ultrastructural Pathology*, 19, 101-106 (1995).

Bruland, Ø.S.: Cancer therapy with radiolabeled antibodies. An overview. *Acta Oncol.*, 34, 1085-1094 (1995).

Olafsen, T., Bruland, Ø.S., Michaelsen, T., Zalutsky, M.R., and Sandlie, I.: Cloning and sequencing of the V-genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. *Nucl. Med. Biol.*, 22, 765-771 (1995).

Larsen, R.H. and Bruland, Ø.S.: Radiolysis of radioimmunoconjugates. Reduction of antigen-binding ability by alpha-particle radiation. *J. Labelled Compds. Radiopharm.*, 36, 1009-1018, 1995.

Gordeladze, J.O., Lund, H.W., Jablonski, G., and Bruland, Ø.S.: Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: Evidence for the involvement of Gi2 in cell proliferation. *J. Cell. Biochemistry*, 60, 95-106 (1996).

Bruland, Ø.S., Skretting, A., Solheim, Ø.P., and Aas, M.: Targeted radiotherapy of osteosarcoma using ¹⁵³Sm-EDTMP. A new promising approach. *Acta Oncol.*, 35, 381-384 (1996).

Hjelstuen, M.H., Rasch-Halvorsen, K., Brekken, C., Bruland, Ø.S., and de L. Davis, C.: Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography. *Acta Oncol.*, 35, 273-279 (1996).

Olafsen, T., Bruland, Ø.S., T., Zalutsky, M.R., and Sandlie, I.: Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3. *Acta Oncol.*, 36, 297-301 (1996).

Moe, L., Boysen, M., Aas, M., Lønnaas, L., Gamlem, H., and Bruland, Ø.S.: Maxillectomy and targeted radionuclide therapy with ¹⁵³Sm-EDTMP in a recurrent canine osteosarcoma. *J.*

Small Animal Pract., 37, 241-246 (1996).

Sæter, G., Bruland, Ø.S., Follerås, G., Boysen, M., and Høie, J.: Extremity and non-extremity high grade osteosarcoma. The Norwegian Radium Hospital experience during the modern chemotherapy era. *Acta Oncol.*, 35, s8, 129-134 (1996).

Lopes, J.M., Bruland, Ø.S., Bjerkehagen, B., Silva, C.M., Holm, R., Pettersen, E.O., Sobrinho-Simoes, M., Solheim, Ø.P., and Nesland, J.M.: Synovial sarcoma: Immunohistochemical expression of P-glycoprotein and glutathione transferase-pi and clinical drug resistance. *Pathol. Res. Pract.*, 193, 21-36 (1997).

Hassfjell S., Bruland, Ø.S., and Hoff, P.: ²¹²Bi-DOTMP - An alpha particle emitting bone seeking agent for targeted radiotherapy. *Nucl. Med. Biol.*, 24 (3), 231-237 (1997)

Ekstrøm, P.O., Giercksky, K.E., Andersen, A., Bruland, Ø.S., and Slørdal, L.: Intratumoral differences in methotrexate levels within human osteosarcoma xenografts as studied by microdialysis. *Life Sciences*, 61(19), 275-280 (1997).

Bruland, Ø.S., and Pihl, A.: On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. *Eur. J. Cancer*, 33, 1725-1731 (1997).

Larsen, R.H., and Bruland, Ø.S.: Intratumor injection of immunoglobulins labelled with the alpha-emitter ²¹¹At: Analyses of tumor retention, microdistribution and growth delay. *Br. J. Cancer*, 77(7), 1115-1122 (1998).

Bruland, Ø.S. (ed.): Towards the eradication of osteosarcoma metastases: An Odyssey. 1-135 (Proceedings) ISBN 82-91929-02-5 (1998).

Bruland, Ø.S., and Pihl, A.: The many faces of osteosarcoma. Some dilemmas and challenges in its current management. 9-15 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Hassfjell, S., Skretting, A., Bruland, Ø.S., and Hoff, P.: Predicting detectability in radioguided surgery: A study based on physical characterization of the probe and on tissue uptake ratios of ¹²⁵I-, ¹⁵³Sm- and ¹⁶⁵Er-labeled radiopharmaceuticals. *Nucl. Med. Communic.*, 19, 207-217 (1998).

Larsen, R.H. and Bruland, Ø.S.: Preliminary evaluation of a new radiolabeled bisphosphonate. *J. Labelled Compds. Radiopharm.*, 51, 823-830 (1998).

Olsen, D.R., and Bruland, Ø.S.: Radiotherapy in Scandinavia. *Acta Oncol.*, 37(6), 553-560 (1998).

Lopes, J.M., Hannisdal, E., Bjerkehagen, B., Bruland, Ø.S., Danielsen, H.E., Pettersen, E.O., Sobrinho-Simoes, M., and Nesland, J.M.: Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. *Anal. Cell. Pathol.*, 16, 45-62 (1998).

Olafsen, T., Rasmussen, I.B., Norderhaug, L., Bruland, Ø.S., and Sandlie, I.: IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eucaryotic cells.

Immunotechnology, 4, 141-153 (1998).

Sæter, G., and Bruland, Ø.S.: High grade osteosarcoma: The scope beyond the classical patient. 21-23 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Høie, J., Sæter, G., Bruland, Ø.S., and Solheim, Ø.P.: Selection of patients for thoracotomy - Who can be cured by surgery? 62-64 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Bruland, Ø.S., Høifødt, H., Breistøl, K., Sæter, G., and Fodstad, Ø: Micrometastasis in patients with osteosarcoma. Immunomagnetic detection of tumor cells present in peripheral blood and bone marrow aspirates. 65-66 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Aurlien, E., Larsen, R.H., Olsen, D.R., and Bruland, Ø.S.: Selective eradication of micrometastases using astatine-211 labelled antibodies. 70-71 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Hjelstuen, M.H., Rasch-Halvorsen, K., Bruland, Ø.S., and de L. Davis, C.: Uptake, penetration and binding of monoclonal antibodies with increasing affinity in human osteosarcoma multicell spheroids. *Anticancer Res.*, 18, 3153-3162 (1998).

Jemtland, R., Rian, E., Olstad, O.K., Haug, E., Bruland, Ø.S., Bucht, E., and Gautvik, K.M.: Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein. *J. Bone and Mineral Res.*, 14, 904-914 (1999).

Larsen, R.H., Murud, K.M., Akabani, G., Hoff, P., Bruland, Ø.S., and Zalutsky, M.R.: ²¹¹At- and ¹³¹I-labeled bisphosphonates with high in vivo stability and bone accumulation. *J. Nucl. Med.* 40, 1197-1203 (1999).

Aas, M., Moe, L., Gamlem, H., Skretting, A., and Bruland, Ø.S.: Internal radionuclide therapy in dogs with primary osteosarcoma employing ¹⁵³Sm-EDTMP. *Clin. Cancer Res.*, 5, 3148-3152 (1999).

Olafsen, T., Munthe Lund, C.K., Bruland, Ø.S., Sandlie, I., and Michaelsen, T.E.: Complement mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. *Cancer Immunol. Immunother.* 75, 755-783 (1999).

Ree, A.H., Tvermyr, M., Engebraaten, O., Rooman, M., Røsok, Ø., Hovig, E., Meza-Zepeda, L.A., Bruland, Ø.S., and Fodstad, Ø.: Expression of a novel factor of breast cancer cells with metastatic potential. *Cancer Res.*, 59, 4675-4680 (1999).

Murud, K.M., Larsen, R.H., Bruland, Ø.S., and Hoff, P.: The influence of pre-treatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of ²¹¹At- and ¹³¹I-labeled amidobisphosphonates in mice. *Nucl. Med. Biol.*, 26/7, 791-794 (1999).

LeBourgeois, J.P. (on behalf of the Emesis Study Group in Radiotherapy Treatment, Bruland, Ø.S. member): Efficacy of an ondansetron orally disintegrating tablet: A novel formulation of this 5-HT₃ receptor antagonist in the treatment of fractionated radiotherapy-induced nausea

and vomiting. *Clinical Oncology*, 11, 340-347 (1999).

Olsen, D.R., Bruland, Ø.S., and Davis, B.J.: Telemedicine in radiotherapy treatment planning - Requirements and Applications. *Radiotherapy & Oncology*, 54, 255-259 (2000).

Aurlien, A., Larsen, R.H., Olsen, D.R., and Bruland, Ø.S.: Alpha-particle radioimmunotherapy versus external beam irradiation of human osteosarcoma and bone marrow: Analyses of microdosimetry and cell survival. *Int. J. Rad. Biol.*, 76/8, 1129-1141 (2000).

Brekken, C., Hjelstuen, M.H., Bruland, Ø.S., and de L. Davies, C.: Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. *Anticancer Res.*, 20/5, 3513-3519 (2000).

Pihl, A., and Bruland, Ø.S. Oral presentation in science and medicine - An art in decline? *Anticancer Res.*, 20, 2795-2800 (2000).

Ølberg, S, Skretting, A., Bruland, Ø.S., and Olsen D.R.: External irradiation of lung tissue: Dosimetric evaluation employing gel dosimetry. *Phys. Med. and Biol.*, 45, 2761-2770 (2000).

Aurlien, E., Larsen, R.H., Kvalheim, G. and Bruland, Ø.S.: Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate 211-At-Rituximab against non-Hodgkin's lymphoma cells. *Br.J.Cancer*, 83, 1375-1379 (2000).

Brekken, C., Bruland, Ø.S., and de L. Davies, C.: Interstitial fluid pressure in human osteosarcoma xenografts: Significance of implantation site and the response to intratumoral injection of hyaluronidase. *Anticancer Res.*, 20/5, 353503-3512 (2000).

Hassfjell, S., Ingebrigtsen, K, and Bruland, Ø.S.: Synthesis, purification and biodistribution of 205Bi-DOTMP, visualizing bone deposition patterns with autoradiography. *Nucl. Med. Biol.*, 28, 425-433 (2001).

Kvinnsland, Y., Skretting A., and Bruland, Ø.S.: Radionuclide therapy with bone-seeking radiopharmaceuticals: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. *Physics in Med. & Biol.* 46, 1149-1161 (2001).

Onda, M., Olafsen, T., Tsutsumi, Y., Bruland, Ø.S., and Pastan, I.: Cytotoxicity of anti-osteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and truncated Pseudomonas Exotoxin A. *J. of Immunotherapy*, 24, 144-150 (2001).

Kvinnsland, Y., Bruland, Ø.S., Moe, L., and Skretting A.: A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: Application to a study of 89-strontium and 153-samariumEDTMP in a dog with spontaneous osteosarcoma. *Eur. J. Nucl. Med.*, 29, 191-197 (2002).

Anderson, P.M., Wiseman, G.A., Dispenzeri, A., Arndt, C., Hartman, L.C., Smithson, W.A., Mullan, B.P., and Bruland, Ø.S.: High dose 153-samarium Ethylene Diamine Tetramethylene Phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. *J.Clin.Oncology*, 20/1, 189-196 (2002).

Aurlien, E., Kvinnsland, Y., Larsen, R.H., and Bruland, Ø.S.: Radiation doses to non-

Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation. *Int. J. Radiat. Biol.*, 78/2, 133-142 (2002).

Ree, A.H., Bratland, A., Kroes, R.A., Aasheim, H.C., Flørenes, V.A., Moskal, J.R., Fodstad, Ø., Bruland, Ø.S., and Mælandsmo, G.M.: Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. *Anticancer Res.*, 22, 1949-1958 (2002).

Chow, E, Jackson, S.Y., Hoskin, P., Cola, L.R., Bentzen, S.M., Blitzer, P.H (on behalf of the International Bone Metastases Consensus Working Party - Bruland, Ø.S. member): International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother. Oncology*, 64, 275-80 (2002).

Henriksen, G., Breistøl, K, Bruland, Ø.S., Fodstad, Ø., and Larsen, R.: Significant antitumor effect from bone-seeking, alpha particle-emitting radium-223 demonstrated in an experimental skeletal metastases model. *Cancer Res.*, 62, 3120-3125 (2002).

Dale, E., Hellebust, T.P., Bruland, Ø.S., and Olsen D.R.: Comparative analyses of the dynamic properties of the rectum studied by cryo-sections of human cadavers and pelvic CT-scans of patients. *Br. J. Radiol.*, 76, 104-108 (2003).

Henriksen, G., Fisher, D.R., Roeske, J.C., Bruland, Ø.S., and Larsen, R.H.: Targeting of osseous sites with alpha emitting 223Ra: Comparison with beta emitter 89Sr in mice. *J. Nucl. Med.*, 74/2, 252-259 (2003).

Olstad, O.K., Gautvik, V.T, Reppe, S., Jemtland, R., Rian, E., Ohlsson, C., Bruland, Ø.S., and Gautvik, K.: Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag-PCR subtraction cloning. *Anticancer Res.*, 23/3B, 2201-2216 (2003).

Reith, A., Olsen, D.R., Bruland, Ø.S., Bernder, A., and Risberg, B.: Information technology in action: The example of Norway. *Stud. Health Technol. Inform.* 96, 186-189 (2003).

Henriksen, G., Bruland, Ø.S., and Larsen, R.: Thorium- and actinium polyphosphonate compounds as bone-seeking alpha particle emitting agents. *Anticancer Res.*, 24, 101-106 (2004).

Davies, C.L.D., Lundstrøm, L.M., Frengen, J., Eikenes, L., Bruland, Ø.S., Kaalhus, O., and Brekken, C.: Radiation improves the distribution and uptake of liposomal doxorubicin (Calyx TM) in human osteosarcoma xenografts. *Cancer Res.*, 64 547-553 (2004).

Henriksen, G., Schoultz, B.W., Michaelsen, T.E., Bruland, Ø.S., and Larsen, R.: Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. *Nucl.Med.Biol*, 31 441-449 (2004).

Mikkelsen, I.M., Løkke, C., Flægstad, T., and Bruland, Ø.S.: Interferon-gamma sensitises human osteosarcoma cells to TRAIL mediated apoptosis. *Cancer Genomics & Proteomics*, 1 95-104 (2004).

Eikenes, L., Bruland, Ø.S., Brekken, and Davies, C.deL.: Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. *Cancer Res.*, 64 1555-60 (2004).

Bruheim, S., Bruland, Ø.S., Breistøl, K., Mælandsmo, G.M., and Fodstad, Ø.: Human osteosarcoma xenografts and their sensitivity to chemotherapy. *Pathol. Oncol. Research*, 10/3 133-41 (2004).

Henriksen, G., Bruland, Ø.S., and Larsen, R.: Preparation and preclinical assessment of folate-conjugated radiolabeled antibodies. *Anticancer Res.*, 25 231-36 (2005).

Onda, M., Bruland, Ø.S., and Pastan, I.: TP-3 immunotoxins improve antitumor activity in mouse bearing osteosarcoma. *Clin. Orthop. Related Res. Clin. Orthopaedics and Rel. Res.*, 430 142-148 (2005).

Dale, E., Bruland, Ø.S., and Olsen D.R.: Comparative analyses of the dynamic properties of the bladder studied by repetitive pelvic CT-scans of patients and cryo-sections of cadavers. *Br. J. Radiol.*, 78 528-32 (2005).

Nilsson, S., Balteskard, L., Fosså, S.D., Westlin, J.E., Borch, K.W., Salberg, G., Larsen, R.H., and Bruland, Ø.S.: First clinical experiences with alpha emitter radium-223 in the treatment of skeletal metastases from breast and prostate cancer. *Clin. Cancer Res.* 11(12) 4451-59, (2005).

Bruland, Ø.S., Kleppe, H., Sæter, G., Smeland, S., and Fodstad, Ø.: Hematogenous micrometases in osteosarcoma patients. *Clin. Cancer Res.*, 11(13) 4666-73, (2005).

Norum, J., Bruland, Ø.S., Spanne, O., Bergmo, T., Green, T., Olsen, D.R., Olsen, J.H., Sjøeng, E.E. and Brukow T.: Telemedicine in radiotherapy. A pilot study exploring remote treatment planning and supervision. *Telemedicine*, 11 245-50 (2005).

Brustugun, O.T., Reed, W., Poulsen, J.P and Bruland, Ø.S.: Primary osteosarcoma of the breast. Case reports and review of the literature. *Acta Oncol.*, 44(7) 767-70 (2005).

Eikenes, L., Tari, M., Tufto, I., Bruland, Ø.S., and Davies, C.deL.: Hyaluronidase improves the distribution and uptake of liposomal doxorubicin (Calyx) in human osteosarcoma xenografts. *Br. J. Cancer*, 93 81-88 (2005).

Aksnes, L.H., Hall, K.S., Folleraas, G., Stenwig, A.E., Bjerkehagen, B., Taksdal, I., Winderen, Bruland Ø.S., and Saeter, G.: Management of high grade bone sarcomas over two decades: The Norwegian Radium Hospital experience. *Acta Oncol.*, 45 38-46 (2006).

Dahle, J., Borrebæk, J., Melhus, K.M., Bruland, Ø.S., Salberg, G., Olsen, D.R., and Larsen, R.H.: -radioimmunotherapy of lymphoma: Preclinical studies of? 227Th-DOTA-rituximab in Balb/c mice. *Nucl. Med & Biol.*, 33 271-9 (2006).

Kaasa, S., Brenne, E., Lund, J-Aa, Fayers, P., Falkmer, U., Wallgren, A., Glas, U., and Bruland, Ø.S.: Prospective randomised multicenter trial on single fraction radiotherapy (8Gyx1) versus multiple fractions (3Gyx10) in the treatment of painful bone metastases. *Radiotherapy & Oncology*, 79, 278-84 (2006).

Larsen, R.H., Saxtorp, H., Skydsgaard, M., Borrebæk, J., Jonasdottir, T.J., Bruland, Ø.S., Klastrup, S. Harling, R., and Ramdahl, T.: Radiotoxicity of the alpha-emitting bone-seeker radium-223 injected intravenously in mice: Histology, clinical chemistry and haematology. *In Vivo*, 20(3), 325-31 (2006).

Jonsdottir, T.J., Fisher, D.R., Borrebæk, J., Bruland, Ø.S., and Larsen, R.H.: First in vivo evaluation of liposome-encapsulated Radium-223 as a potential alpha-particle-emitting cancer therapeutic agent. *Anticancer Res.*, 26, 2841-8 (2006).

Bruland, Ø.S., Nilsson, S., Fisher, D.R., and Larsen, R.H.: High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter ²²³Ra: adjuvant or alternative to conventional modalities? *Clin Cancer Res* 12(20), 6250s-6257s (2006).

Malinen, E., Søvik, Å., Hristov, D., Bruland, Ø.S., and Olsen, D.R. Adapting radiotherapy to hypoxic tumours. *Phys. Medicine & Biology*, 51, 4903-21 (2006).

Bruland, Ø.S., Nilsson, S., Fisher, D.R., and Larsen, R.H. High-linear energy-transfer irradiation targeted to skeletal metastases by the alpha emitter ²²³Ra: Adjuvant or alternative to conventional modalities? *Clin Cancer Res.*, *Clin Cancer Res* 12(20), 6250s-6257s (2006).

Lipton, A., Berenson, J.R., Body, J.J., Boyce, B.F., Bruland, Ø.S., Carducci, M.A., Cleeland, C.S., Clohisy, D.R., Coleman, R.E., Cook, R.J., Guise, T.A., Pearse, R.N, Powles, T.J., Rogers, M.J., Roodman, G.D., Smith, M.R., Suva, L.J., Vessella, R.L., Weillbaeher, K.N., and King, L.: Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference. *Clin Cancer Res* 12(20), 6209s-6212s (2006).

Olsen, D.R., Bruland, Ø.S., Frykholm, G., and Norderhaug I.N.: Proton therapy - A systematic review of clinical effectiveness. *Radiother Oncol*, 83, 123-32 (2007).

Vassiliou V, Bruland O, Janjan N, Lutz S, Kardamakis D, Hoskin P: Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness. *Clin Oncol (R Coll Radiol)*, 21 (9), 665-7 (2009).

Berg, A., Berner, A., Lilleby, W., Bruland, Ø.S., Fosså, S.D., Nesland, J.N., and Kvalheim, G.: Impact of disseminated tumor cells in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. *Int J Cancer*, 120(8), 1603-9 (2007).

Søvik, Å., Malinen, E., Bruland, Ø.S., Bentzen, S.M., and Olsen, D.R.: Optimization of tumor control probability in hypoxic tumors by radiation dose redistribution. *Phys Med Biol* 52(2):499-513 (2007).

Aksnes, L.H., and Bruland Ø.S.: Some musculo-skeletal sequelae in cancer survivors. *Acta Oncol* 46(4), 490-6 (2007).

Porojnicu, A.C., Robsahm, T.E., Dahlback, A., Berg, J.P., Christiani, D., Bruland, Ø.S, and Moan, J.: Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? *Lung Cancer* 55(3), 263-70 (2007).

Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, Bruland OS: Preparation

of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. *Cancer Biother Radiopharm* 22(3):431-7 (2007).

Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH: Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. *Blood* 110(6):2049-56 (2007).

Søvik, Å., Malinen, E., Skogmo, H.K., Bentzen, S.M., Bruland, Ø.S., and Olsen, D.R. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. *Int. J. Radiat. Oncol. Biol. Phys.*, 68(5), 1496-1504 (2007).

Nilsson, S., Franzén, L., Parker, C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D.C., Sokal, M., Pigott, K., Yachnin, J. Garkavij, M., Strang, P., Harmenberg, J., Bolstad, B., and Bruland, Ø.S.: Bone-targeted radium-223 in symptomatic, hormone refractory prostate cancer: A randomized, placebo-controlled, phase 2 study. *Lancet Oncol.* 8(7), 587-94 (2007).

Berg A, Lilleby W, Bruland OS, and Fosså SD: 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. *Int J Radiat Oncol Biol Phys* 69(4):1074-83 (2007).

Erikson A, Tufto I, Bjønnum AB, Bruland, ØS, Davies Cde L: The impact of enzymatic degradation on the uptake of differently sized therapeutic molecules. *Anticancer Res*, 28 (6A), 3557-66(2008).

Dahle J, Bruland OS, and Larsen RH: Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. *Int J Radiat Oncol Biol Phys* 72(1):186-92 (2008).

Berg A, Bruland OS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W: Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. *Prostate* 68 (15), 1607-14 (2008).

Søvik A, Kippenes Skogmo H, Bruland ØS, Rune Olsen D, Malinen E: DCEMRI monitoring of canine tumors during fractionated radiotherapy. *Acta Oncol* 47(7):1249-56 (2008).

Porojnicu AC, Bruland OS, Aksnes L, Grant WB, Moan J: Sun beds and cod liver oil as vitamin D sources. *J Photochem Photobiol B* 91(2-3):125-31 (2008).

Vågane R, Bruland ØS, Fosså SD, Olsen DR: Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation. *Acta Oncol* 47(2):248-54 (2008).

Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, Alvegård T, Bruland OS: Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. *Int J Radiat Oncol Biol Phys* 71(4):1196-203 (2008).

Bruland OS, Jonasdottir TJ, Fisher DR and Larsen RH. Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy. *Current Radiopharmaceuticals*, 1, 203-208 (2008).

Bruland, Ø.S., Dahle, J., Olsen, D.R., and Larsen, R.H.: Targeted high-LET therapy of bone metastases. In: Targeted radionuclide tumor therapy - Biological aspects. Stigbrand, Adams & Carlsson (eds.). Springer Verlag. ISBN 978 1 4020 8695 3, pp. 181-194 (2008).

Bruland ØS, Hird A, and Chow E: Radiotherapy of Skeletal Metastases. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th Edition. The American Society for Bone & Mineral Research. ISBN 978 0 977 8882 1 4, pp. 404-406 (2008).

Jaffe, Norman; Bruland, Øyvind S. and Bielack, Stefan (eds.) Pediatric and Adolescent Osteosarcoma. Series: Cancer Treatment and Research , Vol. 152 , ISBN: 978-1-4419-0283-2, 2009.

Berg A, Dahl AA, Bruland ØS, Bjørø T, Aanensen MS, Fosså SD: Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes. *Prostate Cancer Prostatic Dis*, 12 (3), 269-76 (2009).

Bruland ØS, Høifødt H, Hall KS, Smeland S, and Fodstad Ø: Bone Marrow Micrometastases Studied by an Immunomagnetic Isolation Procedure in Extremity Localized Non-metastatic Osteosarcoma Patients. *Cancer Treatment and Research*. Vol. 152, 509-515, (2009).

Brandal P, Bjerkehagen B, Bruland OS, Skjeldal S, Bogsrud TV, Hall KS: Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience. *Acta Oncol*, 48 (8), 1165-72 (2009).

Hall KS, Eriksson M, Bruland OS, Engellau J, Trovik CS: Treatment of soft tissue sarcoma of the extremity and trunk wall The Scandinavian Sarcoma Group perspective. *Acta Orthop.*, 80 S334, 52-59 (2009).

Norum OJ, Bruland ØS, Gorunova L, Berg K: Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model. *Int J Radiat Oncol Biol Phys*, 75 (3), 878-85 (2009).

Revheim ME, Seierstad T, Berner JM, Bruland OS, Røe K, Ohnstad HO, Bjerkehagen B, Bach-Gansmo T: Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. *Anticancer Res*, 29 (11), 4331-6 (2009).

Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S: Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial. *Radiother Oncol*, 91 (2), 261-6 (2009).

Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA: Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol. *Acta Orthop.*, 80 S334, 60-66 (2009).

Søvik S, Skogmo HK, Andersen EK, Bruland ØS, Olsen DR, Malinen E: DCEMRI of

spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis. *Radiother Oncol*, 93 (3), 618-24 (2009).

Bruland ØS, Bauer H, Alvegaard T, and Smeland S: Treatment of Osteosarcoma. The Scandinavian Sarcoma Group Experience. In: Jaffe, Norman; Bruland, Øyvind S.; Bielack, Stefan (Eds.) *Pediatric and Adolescent Osteosarcoma*. Series: *Cancer Treatment and Research*, Vol. 152, ISBN: 978-1-4419-0283-2, pp. 309-318 (2009).

Schwarz R, Bruland OS, Cassoni A, Schomberg P, and Bielack S: The Role of Radiotherapy in Osteosarcoma. In: Jaffe, Norman; Bruland, Øyvind S.; Bielack, Stefan (Eds.) *Pediatric and Adolescent Osteosarcoma*. Series: *Cancer Treatment and Research*, Vol. 152, ISBN: 978-1-4419-0283-2, pp. 147-164 (2009).

Cicarma E, Juzeniene A, Porojnicu AC, Bruland ØS, Moan J: Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966-2007. *J Photochem Photobiol B*, 101 (2), 174-8 (2010).

Müller CR, Namløs HM, Bjerner J, Østensen IHG, Sæter G, Smeland S, Bruland ØS, Myklebost O: Characterization of Treatment Response to Recombinant Interferon- α 2b in Osteosarcoma Xenografts. *Journal of Cancer Science & Therapy* 2: 16-25 (2010).

Moan J, Lagunova Z, Bruland O, Juzeniene A: Seasonal variations of cancer incidence and prognosis *Dermatoendocrinol*, 2 (2), 55-7(2010).

Dale E, Hårsaker V, Kristoffersen DT, Bruland O, Olsen DR: CT Density in Lung Cancer Patients After Radiotherapy Sensitized by Metoclopramide : A Subgroup Analysis of a Randomized Trial. *Strahlenther Onkol*, 186 (3), 163-168 (2010).

Lagunova Z, Porojnicu AC, Grant WB, Bruland Ø, Moan JE: Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? *Mol Nutr Food Res*, 54 (8), 1127-33 (2010).

Moan J, Bruland ØS, Dahlback A, Juzeniene A and Porojnicu AC: Vitamin D status, solar radiation and cancer prognosis. In: *Nutrition and Health: Vitamin D*. Holick MF (Ed.) ISBN 978-1-60327-300-8. Humana Press, Springer 765-776 (2010).

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J: Experimental alpha-particle radioimmunotherapy of breast cancer using ^{227}Th -labeled p-benzyl-DOTA-trastuzumab. *EJNMMI Res*, 1 (1), 18 (2011).

Anfinsen KP, Grotmol T, Bruland OS and Jonasdottir TJ: Breed specific incidence rates of canine primary bone tumours – a population based survey of dogs in Norway. *Canadian Journal of Veterinary Research*. *Can J Vet Res*, 75 (3), 209-15 (2011).

Mikalsen LT, Dhakal HP, Bruland OS, Nesland JM, Olsen DR: Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections. *Anticancer Res*, 31 (12), 4053-60 (2011).

Revheim ME, Hole KH, Bruland OS, Haugland HK, Hall KS, Seierstad T. DW MRI for

evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour. *Acta Oncol*, 50 (1), 148-50 (2011).

Jebsen NL, Bruland OS, Eriksson M, Engellau J, Turesson I, Folin A, Trovik CS, Hall KS: Five-Year Results From a Scandinavian Sarcoma Group Study (SSG XIII) of Adjuvant Chemotherapy Combined With Accelerated Radiotherapy in High-Risk Soft Tissue Sarcoma of Extremities and Trunk Wall. *Int J Radiat Oncol Biol Phys*. 81 (5), 1359-66 (2011).

Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Österlundh G, Jakobson Å, Sundby Hall K, Monge OR, Björk O and Alvegaard TA. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. *Acta Orthop.*, 82, (2), 211-6 (2011).

Anfinsen KP, Devesa SS, Bray F, Troisi R, Jonasdottir TJ, Bruland OS and Grotmol T: Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976 – 2005). *Cancer Epidemiol Biomarkers Prev*, 20 (8), 1770-7 (2011).

Zaikova O, Fosså SD, Bruland OS, Giercksky KE, Sandstad B, Skjeldal S: Radiotherapy or surgery for spine metastases? *Acta Orthop*, 82 (3), 365-71 (2011)

Revheim ME, Røe K, Bruland OS, Bach-Gansmo T, Skretting A, Seierstad T: Monitoring the Effect of Targeted Therapies in a Gastrointestinal Stromal Tumor Xenograft Using a Clinical PET/CT. *Mol Imaging Biol* 13 (6), 1234-40 (2011).

Dahle J, Abbas N, Bruland ØS, Larsen RH: Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates. *Curr Radiopharm*, 4 (4), 321-8 (2011).

Sartor O, Goeckeler W and Bruland O: Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. *Asian J Androl* 13 (6), 783-4 (2011).

Dahle J, Abbas N, Bruland ØS, Larsen RH: Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates. *Curr Radiopharm*, 4 (4), 321-8 (2011).

Sartor O and Bruland O: Stromal targeted therapies in prostate and renal cancers: New concepts and knowledge. *Clinical Genitourinary Cancer* 9 (1), 1-2 (2011).

Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O: Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. *Sarcoma*, 2012, 639038 (2012).

S Nilsson , P Strang, L Franzèn, P Oliver, A Pecking, J Staffurth, S Vasanthan, C Andersson, AK Aksnes and ØS Bruland: A double-blind, randomised dose-response phase II, multicentre study of radium-223 (Alpharadin[®]) for the palliation of painful bone metastases in castration resistant prostate cancer patients. *Eur J Cancer*, *Eur J Cancer*, 48 (5), 678-86 (2012)

Abbas N, Bruland ØS, Brevik EM, Dahle J: Preclinical evaluation of ²²⁷Th-labeled and ¹⁷⁷Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. *Nucl Med Commun*, 33 (8), 838-47 (2012).

Bruland ØS and Sartor O: Radioisotope treatments for bone metastases. In: *Handbook of*

Cancer-Induced Bone Disease. Comenan, Abrahamsson & Hadji (eds.) 2 nd edition ISBN-10: 1-901978-34-6. BioScientifica 203-221 (2012).

Micu E, Baturaite Z, Juzeniene A, Bruland ØS, Moan JE: Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients. *Melanoma Res*, 22 (6), 460-5 (2012).

Abbas N, Bruland ØS, Brevik EM, Dahle J: Preclinical evaluation of ²²⁷Th-labeled and ¹⁷⁷Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. *Nucl Med Commun*, 33 (8), 838-47 (2012)

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH: Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. *Anticancer Res*, 33 (1), 85-95 (2012)

Micu E, Baturaite Z, Juzeniene A, Bruland ØS, Moan JE: Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients *Melanoma Res*, 22 (6), 460-5 (2012)

Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O: Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. *Sarcoma*, 2012/639038 (2012)

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland ØS: Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. *Clin Genitourin Cancer*, 11 (1), 20-6 (2012)

Nilsson S, Strang P, Aksnes AK, Franzén L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland ØS: A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. *Eur J Cancer*, 48 (5), 678-86 (2012)

Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E: Quantitative dynamic ¹⁸F-FDG-PET and tracer kinetic analysis of soft tissue sarcomas. *Acta Oncol*, 52 (6), 1160-7 (2012)

Sartor O, Hoskin P, Bruland OS: Targeted radio-nuclide therapy of skeletal metastases. *Cancer Treat Rev*, 39 (1), 18-26 (2012)

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH: Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma. *Anticancer Res*, 33 (1), 85-95(2013)

Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J: Comparing high LET ²²⁷Th- and low LET ¹⁷⁷Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. *Curr*

Radiopharm, 6 (2), 78-86 (2013)

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD: Incidence and mortality of second sarcomas - a population-based study. *Eur J Cancer*, 49 (15), 3292-302 (2013)

Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim S, Bruland OS, Hall KS, Tierens A, Delabie J: Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin. *Case Rep Hematol*, 2013, 934781 (2013)

Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J: Targeted alpha therapy with ²²⁷Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. *Curr Radiopharm*, 6 (2), 106-16 (2013)

Chow E, Hird A and Bruland OS: Radiotherapy of Skeletal Metastases. Chapter 86 in *ASBMR-primer*; 8th Edition. American Society for Bone and Mineral Research (2013)

Jebsen NL, Engellau J, Engström K, Bauer HC, Monge OR, Muren LP, Eide GE, Trovik CS, Bruland OS: Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. *Int J Radiat Oncol Biol Phys*, 86 (5), 949-55 (2013)

Lagunova Z, Porojnicu AC, Aksnes L, Holick MF, Iani V, Bruland OS, Moan J: Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial. *Br J Dermatol*, 169 (2), 434-40 (2013)

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR: The clinical impact of mean vessel size and solidity in breast carcinoma patients. *PLoS One*, 8 (10), e75954 (2013)

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannesen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Bruland OS, Sartor O: Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*, 369 (3), 213-23 (2013)

Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T: Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. *Acta Oncol*, 53 (1), 143-8 (2013)

Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T: Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. *Acta Oncol*, 52 (4), 776-82 (2013)

Rusten E, Rødal J, Bruland Ø, Malinen E: Biologic targets identified from dynamic ¹⁸F-FDG-PET and implications for image-guided therapy. *Acta Oncol*, 52 (7), 1378-83 (2013)

Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Sæter G, Jørgensen LH, Hall KS: Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome? *Acta Oncol*, 53 (9), 1180-7 (2014)

Repetto-Llamazares A, Abbas N, Bruland ØS, Dahle J, Larsen RH: Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of B-cell tumors *Anticancer Res*, 34 (7), 3263-9 (2014)

Bruland OS and Larsen RH: Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223. Chapter in *Medical Radiology/Radiation Oncology – Volume “Therapeutic Nuclear medicine”* Springer Verlag, R.P.Baum (editor) 447-457 (2014)

Repetto-Llamazares AH, Larsen RH, Giusti AM, Riccardi E, Bruland ØS, Selbo PK, Dahle J: ¹⁷⁷Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice *PLoS One*, 9 (7), e103070 (2014)

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C: Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial *Lancet Oncol*, 15 (7), 738-46 (2014)

Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ, Bruland OS: Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma *Acta Oncol*, 1-9 (in press 2014) PubMed 24957555

Juzenine A, Porojnicu AC, Batuurait Z, Lagunova Z, Aksnes L, Bruland OS and Moan J: Vitamin D Levels and Dietary Intake Among Patients with Benign Soft Tissue Tumours and Sarcomas. *Anticancer Research* 34: In Press (2014)

+ 3 papers submitted / under review, 2014